Okay, let's tackle this question. The question is about why methicillin-resistant staphylococci don't respond to β-lactam antibiotics. First, I need to recall the core concept here. The main idea is antibiotic resistance mechanisms, specifically in MRSA (Methicillin-resistant Staphylococcus aureus). The β-lactam antibiotics work by inhibiting cell wall synthesis, right? They target penicillin-binding proteins (PBPs) which are essential for cross-linking the peptidoglycan layer in bacterial cell walls.

Now, the correct answer should relate to how MRSA has a mechanism to bypass the effect of these antibiotics. I remember that MRSA produces an altered PBP, often called PBP2a or PBP2', which has a lower affinity for β-lactam antibiotics. This allows the bacteria to continue cell wall synthesis even when the antibiotics are present. So the answer is about the presence of an altered PBP that isn't inhibited by the drug.

Looking at the options (even though they aren't provided here), the distractors might include other resistance mechanisms like β-lactamase production, which is more common in other staphylococci but not MRSA. Another wrong option could be about cell membrane changes or efflux pumps, which are mechanisms for other types of resistance. Also, maybe an option about mutation in the target site, but that's more for other antibiotics like vancomycin.

The clinical pearl here is that MRSA's resistance is specifically due to the mecA gene encoding PBP2a. It's crucial to differentiate this from other resistance mechanisms. For exams, remembering that β-lactam resistance in MRSA is due to altered PBPs, not β-lactamase production, is key. So the correct answer would highlight the presence of this altered PBP.

**Core Concept**
Methicillin-resistant *Staphylococcus aureus* (MRSA) resists β-lactam antibiotics due to a **genetic adaptation** involving the *mecA* gene. This gene encodes **PBP2a (penicillin-binding protein 2a)**, an altered penicillin-binding protein with **low affinity** for β-lactam drugs, bypassing their inhibitory effect on cell wall synthesis.

**Why the Correct Answer is Right**
MRSA acquires the *mecA* gene (or *mecC* in rare cases) from the **Staphylococcal cassette chromosome mec (SCCmec)**. PBP2a is a **low-affinity PBP** that continues transpeptidation (cross-linking of peptidoglycan) even in the presence of β-lactams like methicillin, oxacillin, or cephalosporins. This **bypasses the normal cell wall synthesis inhibition** mechanism of β-lactams, rendering them ineffective.

**Why Each Wrong Option is Incorrect**
**Option A:** *β-lactamase production* is incorrect because MRSA resistance is **not primarily due to β-lactamase** (which degrades β-lactam rings). β-lactamase is a mechanism in methicillin-susceptible *S. aureus* (MSSA), not MRSA.
**Option B:**

✓ Correct Answer: B. They elaborate an amidase which destroys methicillin and related drugs.